Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TremRx Inc.

Looking back to the future of vaccine development

This article was originally published in Start Up

Executive Summary

Fresh evidence that everything once fashionable eventually comes back into style is now provided by TremRx Inc., a Boston-based start-up intent on developing prophylactic and therapeutic vaccines. The company’s approach hinges on much the same method as the smallpox vaccine invented by Edward Jenner in the late 1700s. As Jenner did, TremRx anticipates its vaccines will be applied to a small area of abraded skin. The company plans to deliver, via this abrasion in the epidermis, a live Vaccinia virus that can infect, but not replicate, in skin cells. Used this way as a vector to carry antigens, the method has been shown to stimulate production of protective immune-system cells called T-Resident Effector Memory cells, or TREMs.

You may also be interested in...

Vaccine Investment Gets A Shot In The Arm

The vaccine industry has had its ups and downs the last two decades, as public opinion and investor perception has influenced both the use and production of these preventative medicines. It’s traditionally been a difficult space for smaller companies due to the financial hurdles, but a handful of start-ups, including TremRx, Selecta Biosciences Inc., Genocea Biosciences Inc. and Imaxio SA, all profiled in this issue, are banking on progress in delivery and development technology to help them raise financing for their vaccines programs.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts